MedPath

Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease.

Not Applicable
Recruiting
Conditions
Crohn Disease
Spondyloarthritis
Interventions
Other: Microbiota Sequencing
Registration Number
NCT03983473
Lead Sponsor
Central Hospital, Nancy, France
Brief Summary

The MICROSPA project aims to compare gut microbiota, serum cytokines, and PBMC of patients suffering from Crohn's disease (CD) associated or not to spondylarthritis (SpA). 3 groups of patients will be analyzed: patients suffering from CD alone, patients suffering from SpA alone, patients suffering from CD and SpA. One group of healthy controls will be analysed as a comparator. Fecal microbiota will be determined by bacteriome, virome and fungome NGS sequencing

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
240
Inclusion Criteria
  • Age ≥ 18 years.
  • Patients will be recruited according to 3 groups:
  • Patients with Crohn's disease and axial spondyloarthritis according to the criteria below.
  • Patients with Crohn's disease (MC patients) with a diagnosis established according to clinical, biological criteria, radiological, endoscopic and / or histological studies for 3 months. With diagnosis of exclusion of a spondyloarthritis on criteria ASAS and / or New York modified.
  • Patients with axial spondyloarthritis (SpA patients) with a diagnosis based on modified ASAS and / or New York criteria with exclusion diagnosis of Crohn's disease.
  • Patient with the ability to give free and express informed consent.
Exclusion Criteria
  • History of colonic resection
  • Taking antibiotics or colon preparation for colonoscopy within 8 weeks before stool collection (Temporary contraindication = removal possible before colic or first bowel preparation after the start of colonic preparation).
  • Ostomy at the time of sampling
  • BMI> 30
  • extreme diet
  • unbalanced diabetes
  • Pregnant woman
  • Patient under guardianship, under curatorship or under the protection of justice Contacts/Locations Central Contact

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Crohn's diseaseMicrobiota SequencingPatients suffering from established Crohn 's disease without spondyloarthritis
SpondyloarthritisMicrobiota SequencingPatients with established spondyloarthritis without Crohn 's disease
Healthy controlsMicrobiota SequencingPatients without spondyloarthritis and Crohn 's disease
Crohn + spondyloarthritisMicrobiota SequencingPatients suffering from both spondyloarthritis and Crohn 's disease
Primary Outcome Measures
NameTimeMethod
Alpha and Beta diversity of Fecal fungome+ 6 months

Alpha (number of species) and Beta diversity (distribution of species)

Alpha and Beta diversity of Fecal bacteriome+ 6 months

Alpha (number of species) and Beta diversity (distribution of species)

Alpha and Beta diversity of Fecal virome+ 6 months

Alpha (number of species) and Beta diversity (distribution of species)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Central Hospital

🇫🇷

Nancy, Lorraine, France

Saint Antoine Hospital

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath